Amylin
Pharmaceuticals, Inc. AMLN and Eli Lilly and Company LLY
today announced that the Committee for Medicinal Products for Human Use (CHMP)
of the European Medicines Agency (EMA) has issued a positive opinion in the
European Union (EU) for the expanded use of BYETTA® (exenatide twice-daily) as
an add-on therapy to basal insulin, with or without metformin and/or Actos®
(pioglitazone), for the treatment of type 2 diabetes in adults who have not
achieved adequate glycemic control with these agents. The CHMP's decision is
now referred for final action to the European Commission, which has the
authority to approve medicines for the EU. The Commission usually decides on
CHMP recommendations within two to three months.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in